Table 3.
Cytotoxicity of the different erythrolides isolated in this study against the cancer cell lines A549 (human lung cancer), MCF7 (human breast adenocarcinoma), and PC3 (human prostate cancer). Data are presented as the mean ± SE IC50 (µM) for the identified chemotypes.
| ID | IC50 A549 (µM) | IC50 MCF7 (µM) | IC50 PC3 (µM) |
|---|---|---|---|
| erythrolide A | 18.41 ± 3.15 | 6.77 ± 0.98 | 2.45 ± 0.38 |
| erythrolide B | 27.09 ± 4.26 | 15.21 ± 2.31 | 6.46 ± 0.96 |
| erythrolide D | 2.58 ± 0.72 | 42.45 ± 4.34 | 60.00 ± 5.55 |
| erythrolide E | 148.22 ± 12.27 | 73.87 ± 5.03 | 189.11 ± 14.93 |
| erythrolide F | 46.49 ± 7.93 | 116.44 ± 12.97 | >120 |
| erythrolide I | >120 | >120 | >120 |
| erythrolide J | 37.93 ± 3.91 | 56.06 ± 3.88 | 42.49 ± 3.53 |
| erythrolide R | 75.28 ± 18.31 | >120 | >120 |
| erythrolide U | 36.65 ± 5.84 | 124.79 ± 15.01 | >120 |
| erythrolide V | 101.72 ± 20.72 | >120 | >120 |
| erythrolide W | >120 | >120 | >120 |
| erythrolide X | >120 | >120 | >120 |
| 16-acetyl erythrolide H | >120 | 113.11 ± 16.04 | >120 |